A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Terminated · Phase 2 · NCT04677179
Conditions: Colitis, Ulcerative
At a glance
- Research payments reported, 2025
- $4,059
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 81
About the trial
- Sponsor
- Nektar Therapeutics (with Eli Lilly and Company)
- Tested
- LY3471851 (drug), Placebo (drug)
- Dates
- Started 2021-03-22; completion 2022-08-09
- Results posted
- Yes
The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.
From ClinicalTrials.gov, last updated 2023-09-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $4,059 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Care Access Research LLC $4,059
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.